Document Detail


Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.
MedLine Citation:
PMID:  11046097     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Because part of the cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitors results from their protective effects on cardiac bradykinin (BK) metabolism, the purpose of this study was to define the metabolism of BK in normal and failing human hearts and to compare the effect of omapatrilat, a vasopeptidase inhibitor (VPI), which simultaneously inhibits both neutral endopeptidase (NEP) and ACE, with that of an ACE inhibitor. Exogenous BK at a nanomolar concentration was incubated alone, in the presence of an ACE inhibitor (ramiprilat, 36 nM), or in the presence of a VPI (omapatrilat, 61 nM) with left ventricular membranes prepared from normal donor hearts (n = 7), and hearts from patients with an ischemic (n = 11) or dilated (n = 12) cardiomyopathy (DCM). The half-lives calculated for BK alone (199 +/- 60, 224 +/- 108, and 283 +/- 122 s; P = NS) exhibited similar values for normal, ischemic, and DCM heart tissues, respectively. Ramiprilat significantly increased the half-life of BK (P <.01), but the effect was similar for the three kinds of tissues (297 +/- 104, 267 +/- 157, and 407 +/- 146 s, respectively; P = NS). The potentiating effect of the VPI omapatrilat on the kinetic parameter of BK (478 +/- 210, 544 +/- 249, and 811 +/- 349 s, respectively) was greater than that of the ACE inhibitor (P <.01). Moreover, omapatrilat had a more important potentiating effect with DCM than normal heart membranes (P <.05). These results show that not only ACE but also and mainly NEP play an important role in the degradation of BK in human heart membranes. Omapatrilat, a VPI, has a greater protective effect on BK metabolism than that of a pure ACE inhibitor. Thus, inhibition of both ACE and NEP with omapatrilat could be more cardioprotective than ACE inhibition alone.
Authors:
C Blais; D Fortin; J L Rouleau; G Molinaro; A Adam
Related Documents :
1725197 - Vascular effects of perindopril: from experimental to clinical investigation.
3143437 - Protection of kidney function and decrease in albuminuria by captopril in insulin depen...
20128937 - Maternal low-protein diet during mouse pre-implantation development induces vascular dy...
11229627 - Beneficial effect of verapamil added to chronic ace inhibitor treatment on renal functi...
21505347 - Association between plasma leptin and blood pressure in two population-based samples of...
2362757 - Long-term follow up of clear cornea trabeculectomy.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of pharmacology and experimental therapeutics     Volume:  295     ISSN:  0022-3565     ISO Abbreviation:  J. Pharmacol. Exp. Ther.     Publication Date:  2000 Nov 
Date Detail:
Created Date:  2000-11-02     Completed Date:  2000-11-21     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  0376362     Medline TA:  J Pharmacol Exp Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  621-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / pharmacology
Bradykinin / metabolism*
Cardiomyopathy, Dilated / enzymology,  metabolism*
Cardiovascular Agents / pharmacology
Female
Half-Life
Heart / drug effects*
Humans
Male
Membranes / enzymology,  metabolism
Middle Aged
Myocardial Ischemia / enzymology,  metabolism
Myocardium / enzymology,  metabolism*
Neprilysin / antagonists & inhibitors,  metabolism
Peptidyl-Dipeptidase A / metabolism
Protease Inhibitors / pharmacology*
Pyridines / pharmacology*
Ramipril / analogs & derivatives*,  pharmacology
Thiazepines / pharmacology*
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Cardiovascular Agents; 0/Protease Inhibitors; 0/Pyridines; 0/Thiazepines; 36NLI90E7T/omapatrilat; 6N5U4QFC3G/ramiprilat; EC 3.4.15.1/Peptidyl-Dipeptidase A; EC 3.4.24.11/Neprilysin; L35JN3I7SJ/Ramipril; S8TIM42R2W/Bradykinin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac io...
Next Document:  An alpha(1A)/alpha(1L)-adrenoceptor mediates contraction of canine subcutaneous resistance arteries.